PGC-1α

Choose Selective PGC-1α Inhibitors

PGC-1α Products

All (4)
PGC-1α Inhibitor (1)
PGC-1α Activators (3)
New PGC-1α Products

Catalog No.	Product Name	Information	Product Use Citations
S8528	SR-18292	SR-18292 inhibits PGC-1α gluconeogenic activity and reduces co-activation of HNF4α by modulating the interaction between GCN5 and PGC-1α.	Front Pharmacol, 2021, 12:624402 Cancers (Basel), 2020, 12(9)E2397
S1168	Valproic Acid (NSC 93819) sodium salt	Valproic Acid sodium salt (NSC 93819, Sodium valproate) is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. Valproic acid induces Notch1 signaling in small cell lung cancer (SCLC) cells. Valproic acid is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α.	Sci Total Environ, 2022, 838(Pt 2):155825 Transl Psychiatry, 2022, 12(1):130 Pigment Cell Melanoma Res, 2021, 10.1111/pcmr.13014
S3944	Valproic acid (VPA)	Valproic acid (VPA, 2-Propylvaleric Acid, Valproate) is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. It is also a histone deacetylase (HDAC) inhibitor and is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. Valproic acid activates Notch-1 signaling.	Cell Res, 2022, 10.1038/s41422-022-00668-0 Int J Mol Sci, 2022, 23(8)4213 Front Immunol, 2021, 12:771453
S7447	ZLN005	ZLN005 is a potent and tissue-specific PGC-1α transcriptional activator.	Biomed Pharmacother, 2021, 144:112331 J Mol Neurosci, 2021, 10.1007/s12031-020-01775-6 Stem Cell Reports, 2020, S2213-6711(20)30418-5
S8528	SR-18292	SR-18292 inhibits PGC-1α gluconeogenic activity and reduces co-activation of HNF4α by modulating the interaction between GCN5 and PGC-1α.	Front Pharmacol, 2021, 12:624402 Cancers (Basel), 2020, 12(9)E2397
S1168	Valproic Acid (NSC 93819) sodium salt	Valproic Acid sodium salt (NSC 93819, Sodium valproate) is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. Valproic acid induces Notch1 signaling in small cell lung cancer (SCLC) cells. Valproic acid is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α.	Sci Total Environ, 2022, 838(Pt 2):155825 Transl Psychiatry, 2022, 12(1):130 Pigment Cell Melanoma Res, 2021, 10.1111/pcmr.13014
S3944	Valproic acid (VPA)	Valproic acid (VPA, 2-Propylvaleric Acid, Valproate) is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. It is also a histone deacetylase (HDAC) inhibitor and is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. Valproic acid activates Notch-1 signaling.	Cell Res, 2022, 10.1038/s41422-022-00668-0 Int J Mol Sci, 2022, 23(8)4213 Front Immunol, 2021, 12:771453
S7447	ZLN005	ZLN005 is a potent and tissue-specific PGC-1α transcriptional activator.	Biomed Pharmacother, 2021, 144:112331 J Mol Neurosci, 2021, 10.1007/s12031-020-01775-6 Stem Cell Reports, 2020, S2213-6711(20)30418-5